A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

NCT01937715 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction

Conditions

Metastatic Colorectal Carcinoma

Interventions

DRUG: PF-05212384
DRUG: FOLFIRI regimen
BIOLOGICAL: Bevacizumab
DRUG: FOLFIRI

Sponsor

Pfizer